Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis

Journal of Clinical Investigation

Volumn 116, Issue 9, 2006, Pages 2344-2355

  He, Yun ^a,b   Luo, Yan ^a,c   Tang, Shibo ^a,c   Rajantie, Iiro ^d   Salven, Petri ^d   Heil, Matthias ^e   Zhang, Rong ^a   Luo, Dianhong ^a   Li, Xianghong ^a   Chi, Hongbo ^a   Yu, Jun ^a   Carmeliet, Peter ^f   Schaper, Wolfgang ^e   Sinusas, Albert J ^a   Sessa, William C ^a   Alitalo, Kari ^d   Min, Wang ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BMX ENZYME; ETK ENZYME; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; LIMB PERFUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; HINDLIMB; HUMANS; ISCHEMIA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN-TYROSINE KINASES;

EID: 33748292990     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28123     Document Type: Article

References (46)

1. Baumgartner, I., Schainfeld, R., and Graziani, L. 2005. Management of peripheral vascular disease. Annu. Rev. Med. 56:249-272.
2. Mohler, E.R., 3rd. 2004. The effect of risk factor changes on peripheral arterial disease and cardiovascular risk. Curr. Drug Targets Cardiovasc. Haematol. Disord. 4:259-263.
3. Brevetti, G., et al. 2003. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J. Vasc. Surg. 38:374-379.
4. Heil, M., and Schaper, W. 2004. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ. Res. 95:449-458.
5. Heil, M., and Schaper, W. 2005. Cellular mechanisms of arteriogenesis. EXS. 94:181-191.
6. Tamagnone, L., et al. 1994. BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2. Oncogene. 9:3683-3688.
7. Qiu, Y., Robinson, D., Pretlow, T.G., and Kung, H.J. 1998. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 95:3644-3649.
8. Chau, C.H., et al. 2002. Coordinated Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation. Oncogene. 21:8817-8829.
9. Zhang, R., et al. 2003. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J. Biol. Chem. 278:51267-51276.
10. Pan, S., et al. 2002. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol. Cell. Biol. 22:7512-7523.
11. Tsai, Y.T., et al. 2000. Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol. Cell. Biol. 20:2043-2054.
12. Mao, J., et al. 1998. Tec/Bmx non-receptor tyrosine kinases are involved in regulation of Rho and serum response factor by Galpha12/13. EMBO J. 17:5638-5646.
13. Chen, R., et al. 2001. Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. Nat. Cell Biol. 3:439-444.
14. Qiu, Y., and Kung, H.J. 2000. Signaling network of the Btk family kinases. Oncogene. 19:5651-5661.
15. Kim, O., Yang, J., and Qiu, Y. 2002. Selective activation of small GTPase RhoA by tyrosine kinase Etk through its pleckstrin homology domain. J. Biol. Chem. 277:30066-30071.
16. Bagheri-Yarmand, R., et al. 2001. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J. Biol. Chem. 276:29403-29409.
17. Kiosses, W.B., et al. 2002. A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ. Res. 90:697-702.
18. Qi, J.H., and Claesson-Welsh, L. 2001. VEGF-induced activation of phosphoinositol 3-kinase is dependent on focal adhesion kinase. Exp. Cell Res. 263:173-182.
19. Gille, H., et al. 2000. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration. EMBO J. 19:4064-4073.
20. Dimmeler, S., Dernbach, E., and Zeiher, A.M. 2000. Phosphorylation of the endothelial nitric oxide synthase at Ser-1177 is required for VEGF-induced endothelial cell migration. FEBS lett. 477:258-262.
21. Kureishi, Y., et al. 2000. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6:1004-1010.
22. Ackah, E., et al. 2005. Akt1/protein kinase Bα is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Invest. 115:2119-2127. doi:10.1172/JCI24726.
23. Matsumoto, T., and Claesson-Welsh, L. 2001. VEGF receptor signal transduction. Sci. STKE. 112:RE21.
24. Rajantie, I., et al. 2001. Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol. Cell. Biol. 21:4647-4655.
25. Paavonen, K., et al. 2004. Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing. Mol. Biol. Cell. 15:4226-4233.
26. Schlaeger, T.M., et al. 1997. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 94:3058-3063.
27. Bauer, P.M., et al. 2005. Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 102:204-209.
28. Yu, J., et al. 2005. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc. Natl. Acad. Sci. U. S. A. 102:10999-11004.
29. Arras, M., et al. 1998. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J. Clin. Invest. 101:40-50.
30. Takahashi, T., et al. 1999. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5:434-438.
31. Asahara, T., et al. 1999. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18:3964-3972.
32. Aicher, A., et al. 2003. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9:1370-1376.
33. Hristov, M., Erl, W., and Weber, P.C. 2003. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler. Thromb. Vasc. Biol. 23:1185-1189.
34. Carmeliet, P., et al. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7:575-583.
35. Silvestre, J.S., et al. 2000. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circ. Res. 87:448-452.
36. Sasaki, K., et al. 2002. Evidence for the importance of angiotensin II type 1 receptor in ischemiainduced angiogenesis. J. Clin. Invest. 109:603-611. doi:10.1172/JCI200213055.
37. Johnson, C., Sung, H.J., Lessner, S.M., Fini, M.E., and Galis, Z.S. 2004. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ. Res. 94:262-268.
38. Shibata, R., et al. 2004. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J. Biol. Chem. 279:28670-28674.
39. Sonveaux, P., et al. 2004. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ. Res. 95:154-161.
40. Heil, M., et al. 2004. Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ. Res. 94:671-677.
41. Tang, G., Charo, D.N., Wang, R., Charo, I.F., and Messina, L. 2004. CCR2-/- knockout mice revascularize normally in response to severe hindlimb ischemia. J. Vasc. Surg. 40:786-795.
42. Murohara, T., et al. 1998. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101:2567-2578.
43. Chau, C.H., et al. 2005. Etk/Bmx mediates expression of stress-induced adaptive genes VEGF, PAI-1, and iNOS via multiple signaling cascades in different cell systems. Am. J. Physiol. Cell Physiol. 289:C444-C454.
44. Hudlicka, O. 1991. What makes blood vessels grow? J. Physiol. 444:1-24.
45. Le Noble, F., et al. 2004. Flow regulates arterial-venous differentiation in the chick embryo yolk sac. Development. 131:361-375.
46. Couffinhal, T., et al. 1998. Mouse model of angiogenesis. Am. J. Pathol. 152:1667-1679.